CN103271931A - Compound acetylisovalery tylosin tartrate pellet and preparation method thereof - Google Patents
Compound acetylisovalery tylosin tartrate pellet and preparation method thereof Download PDFInfo
- Publication number
- CN103271931A CN103271931A CN2013101870356A CN201310187035A CN103271931A CN 103271931 A CN103271931 A CN 103271931A CN 2013101870356 A CN2013101870356 A CN 2013101870356A CN 201310187035 A CN201310187035 A CN 201310187035A CN 103271931 A CN103271931 A CN 103271931A
- Authority
- CN
- China
- Prior art keywords
- safe
- tartaric acid
- micropills
- thousand
- compound recipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims description 22
- ICVKYYINQHWDLM-KBEWXLTPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 ICVKYYINQHWDLM-KBEWXLTPSA-N 0.000 title abstract description 8
- 229960001717 tylosin tartrate Drugs 0.000 title abstract description 8
- 239000008188 pellet Substances 0.000 title abstract 7
- 239000003814 drug Substances 0.000 claims abstract description 59
- 239000011248 coating agent Substances 0.000 claims abstract description 36
- 238000000576 coating method Methods 0.000 claims abstract description 36
- 239000011230 binding agent Substances 0.000 claims abstract description 31
- 229920002472 Starch Polymers 0.000 claims abstract description 30
- 239000008107 starch Substances 0.000 claims abstract description 27
- 235000019698 starch Nutrition 0.000 claims abstract description 27
- 229960002135 sulfadimidine Drugs 0.000 claims abstract description 24
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims abstract description 24
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 22
- 239000008101 lactose Substances 0.000 claims abstract description 22
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 22
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 22
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 13
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 72
- 235000002906 tartaric acid Nutrition 0.000 claims description 72
- 239000011975 tartaric acid Substances 0.000 claims description 72
- 238000005469 granulation Methods 0.000 claims description 28
- 230000003179 granulation Effects 0.000 claims description 28
- 238000012216 screening Methods 0.000 claims description 23
- 240000008042 Zea mays Species 0.000 claims description 21
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 21
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 21
- 235000009973 maize Nutrition 0.000 claims description 21
- 235000012054 meals Nutrition 0.000 claims description 21
- -1 hydroxypropyl Chemical group 0.000 claims description 20
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 235000012343 cottonseed oil Nutrition 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 210000003516 pericardium Anatomy 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 229920000609 methyl cellulose Polymers 0.000 claims description 8
- 239000001923 methylcellulose Substances 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 239000007779 soft material Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003087 methylethyl cellulose Polymers 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 238000002156 mixing Methods 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000035611 feeding Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019629 palatability Nutrition 0.000 description 4
- 235000019890 Amylum Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 229930194936 Tylosin Natural products 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000012946 outsourcing Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000012353 Contagious Pleuropneumonia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet is made by wrapping a drug-loading pellet core by adopting a coating material, wherein the drug-loading pellet core comprises the following components in percentage by weight: 1-30% of acetylisovalery tylosin tartrate, 1-30% of sulfadimidine, 5-20% of lactose, 5-25% of corncob powder, 10-60% of starch, 15-35% of microcrystalline cellulose and 0.5-12% of pelletizing binding agent; and weight of the coating material is not more than 8% of the total weight of the compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet has a better clinical treatment effect, application amount of acetylisovalery tylosin tartrate can be reduced, and production cost can be saved; and drug release can be delayed, drug action time can be prolonged, and long-acting effect can be achieved, so that administration frequency is reduced and labour intensity can be alleviated.
Description
Technical field
The present invention relates to safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid and preparation method thereof, belong to the veterinary drug preparation technical field.
Background technology
Safe ten thousand rhzomorphs of tartaric acid are that acetylisovaleryl tylosin (Acetylisovalery Tylosin Tartrate) is by the commercial brand-new macrolide antibiotics of Britain Yi Ke animal health product limited company.Be the derivant that tylosin A generates through chemical improvement, mycoplasma, spirillum, most of gram positive bacteria and part gram negative bacteria are all had stronger antibacterial activity, especially the antibacterial activity to mycoplasma is big especially; Be mainly used in preventing and treating the mycoplasma infection of chicken, turkey and other animal, the dysentery of pig, contagious pleuropneumonia, the disease of breathing, hypertrophy enteritis (PPE) etc. are the special-purpose antibiotic of poultry.
At present, common Thailand's ten thousand rhzomorphs are common pre-mixing agent and soluble powders on the market, because of preparation process simple, make bioavailability of medicament low, be subject to the influence of gastric acid simultaneously, and medicine itself produces serious influence to gastrointestinal tract easily, the ordinary preparation abnormal smells from the patient is big and bitter in the mouth easily disperses again so that palatability difference feed intake descends, so that curative effect of medication reduces, and does not reach ideal effect; On the other hand, simple pre-mixing agent is blended in the feedstuff, easily with feedstuff in multiple components such as acidulant, high-micro-element, electrolyte etc. chemical reaction takes place, make its drug effect decline, and the ordinary preparation administration number of times has increased hand labor intensity; And Chinese patent application number discloses a boar with safe ten thousand rhzomorph injection and preparation method thereof for the patent of invention of " 201110009247.6 "; per 100 milliliters of injection contain 20 gram tartaric acid acetyl-isovaleryl base tylosins, 20～35 gram propylene glycol, 10～15 gram N, the glyceryl triacetate of N-diformyl acetamide, 2～4 gram benzyl alcohol, 0.1～1.0 gram ditertbutylparacresol and surplus.But this boar also exists hand labor intensity big with safe ten thousand rhzomorph injection, and injection to pig can produce very strong stress shortcoming.
Therefore, urgent clinical needs will stablize, safe ten thousand rhzomorph novel formulation of tartaric acid efficient, easy to use, to guarantee its clinical efficacy, strengthen palatability and to alleviate hand labor intensity.
Summary of the invention
At the deficiencies in the prior art, first purpose of the present invention is in order to provide a kind of compound recipe tartaric acid safe ten thousand rhzomorph micropills, and the present invention has better clinical therapeutic efficacy, and can reduce the use amount of safe ten thousand rhzomorphs of tartaric acid, saves production cost; The present invention simultaneously can improve medicine stability, make medicine avoid the influence of feed ingredient and gastric acid, cover the adverse drug abnormal smells from the patient, increase palatability, reducing stimulates gastrointestinal, and good fluidity again the painted clothing layer of outsourcing easily make mixed feeding even, reduced dust, can delay simultaneously the release of medicine, prolong drug action time, play long-acting and alleviate hand labor intensity to reduce administration number of times.
Second purpose of the present invention is for the preparation method of the safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid is provided, and this method has that preparation technology is simple, less energy consumption and the characteristics implemented easily.
Realize that first purpose of the present invention can reach by taking following technical scheme:
The safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid is characterized in that, are made by the coating material parcel medicine carrying ball heart;
1) described medicine carrying ball pericardium is drawn together following components in weight percentage content: the safe ten thousand rhzomorph 1-30% of tartaric acid, sulfadimidine 1-30%, lactose 5-20%, maize cob meal 5-25%, starch 10-60%, microcrystalline Cellulose 15-35%, granulation binders 0.5-12%;
2) described coating material weight is no more than 8% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid; Coating material is selected from one or more in hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, sodium carboxymethyl cellulose, methylethylcellulose, Polyethylene Glycol, the polyvinylpyrrolidone.
Preferably, described medicine carrying ball pericardium is drawn together following components in weight percentage content: the safe ten thousand rhzomorph 5-20% of tartaric acid; Sulfadimidine 5-20%; Lactose 10-15%; Maize cob meal 10-20%; Starch 20-50%; Microcrystalline Cellulose 15-30%; Granulation binders 1-8%.
Preferably, the described medicine carrying ball heart is that size is not more than 30 purpose micropartical.
Preferably, described granulation binders is selected from one or more the compositions in gelatin, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, methylcellulose, ethyl cellulose or the starch slurry.
Realize that second purpose of the present invention can reach by taking following technical scheme:
The preparation method of the safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid is characterized in that carrying out according to the following steps:
1) by one or more the compositions in prescription weighing gelatin, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, methylcellulose, ethyl cellulose or the starch, as granulation binders;
2) by safe ten thousand rhzomorphs of prescription weighing tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose and mix homogeneously, add step 1) gained granulation binders again and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, sieves out 30-50 purpose screening thing after the drying;
4) the one or more combination thing in hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, sodium carboxymethyl cellulose, methylethylcellulose, Polyethylene Glycol, the polyvinylpyrrolidone being prepared in advance solid content is 10% coating solution, then step 3) gained screening thing is sprayed into and carry out Cotton seeds in the coating solution, coated back is continued dry, namely gets the safe ten thousand rhzomorph micropills of described tartaric acid.
Preferably, in step 3), the described medicine carrying ball heart is put into fluid bed carry out drying.
Preferably, in step 4), the screening thing that screening is good is put into fluid bed, and inlet temperature is 40-60 ℃, sprays into the coating solution Cotton seeds, dry 15-30 minute of the follow-up afterflowization of coating.
Beneficial effect of the present invention is:
1, Thailand's ten thousand rhzomorphs in the present invention's prescription belong to the fast antibacterial of imitating, and sulfadimidine is the wide spectrum effect type slowly antibacterial that suppresses its growth and breeding by the folic acid metabolism that disturbs sensitive organism, both share, and can obtain accumulative action, remedy antimicrobial spectrum weak point separately.Simultaneously safe ten thousand rhzomorphs of tartaric acid, sulfadimidine have been made micropill, had better clinical therapeutic efficacy, and can reduce the use amount of safe ten thousand rhzomorphs of tartaric acid, saved production cost; The present invention simultaneously can improve medicine stability, make medicine avoid the influence of feed ingredient and gastric acid, cover the adverse drug abnormal smells from the patient, increase palatability, reducing stimulates gastrointestinal, and good fluidity again the painted clothing layer of outsourcing easily make mixed feeding even, reduced dust, can delay simultaneously the release of medicine, prolong drug action time, play long-acting and alleviate hand labor intensity to reduce administration number of times.Can avoid safe ten thousand rhzomorphs of tartaric acid on veterinary clinic unfavorable and give full play to its effect; On the other hand, medication is convenient, and the spice adding gets final product, and does not influence the feed intake of animal.
2, to have technology simple for the safe ten thousand rhzomorph microsphere and its preparations of compound recipe tartaric acid of the present invention, less energy consumption, and production safety realizes the even-grained advantage of the micropill that makes easily.
The specific embodiment
Below, in conjunction with the specific embodiment, the present invention is described further:
Embodiment 1:
The safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid comprise coating and the medicine carrying ball heart, and the described medicine carrying ball heart is that size is not more than 30 purpose micropartical, and wherein medicine carrying ball pericardium contains the component of following percetage by weight: safe ten thousand rhzomorphs 2% of tartaric acid; Sulfadimidine 2%; Lactose 10%; Maize cob meal 10%; Starch 58%; Microcrystalline Cellulose 15%; Granulation binders 3%.
Wherein, described granulation binders is gelatin adhesive.Described coat weight is 2% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid, and wherein coating material is hydroxypropyl emthylcellulose.
The preparation method of the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid comprises following concrete steps:
1) by following each component of following percentage by weight difference weighing: safe ten thousand rhzomorphs 2% of tartaric acid, sulfadimidine 2%, lactose 10%, maize cob meal 10%, starch 58%, microcrystalline Cellulose 15%, gelatin granulation binders 3%.With safe ten thousand rhzomorphs of tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose mix homogeneously;
2) add in the gelatin granulation binders for preparing in the step 1) gained mixture and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, dry back screening 30-50 purpose screening thing;
4) step 3) gained screening thing is put into fluid bed, inlet temperature is 45 ℃, and 30 ℃ of leaving air temps spray into the coating solution that modulates with hydroxypropyl emthylcellulose and carry out Cotton seeds, continued dry 20 minutes coated back, namely gets the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid.The solid content of coating solution is 10%.
Embodiment 2:
The safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid, comprise coating and the medicine carrying ball heart, the described medicine carrying ball heart is that size is not more than 30 purpose micropartical, wherein medicine carrying ball pericardium contains the component of following percetage by weight: safe ten thousand rhzomorphs 5% of tartaric acid, sulfadimidine 5%, lactose 15%, maize cob meal 10%, starch 44%, microcrystalline Cellulose 15%, granulation binders 6%.
Wherein, described granulation binders is amylum adhesive.Described coat weight is 3% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid, and wherein coating material is methylcellulose.
The preparation method of the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid comprises following concrete steps:
1) by following each component of following percentage by weight difference weighing: safe ten thousand rhzomorphs 5% of tartaric acid, sulfadimidine 5%, lactose 15%, maize cob meal 10%, starch 44%, microcrystalline Cellulose 15%, amylum adhesive 6%.With safe ten thousand rhzomorphs of tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose mix homogeneously;
2) add the amylum adhesive for preparing in the step 1) gained mixture and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, dry back screening 30-50 purpose screening thing;
4) step 3) gained screening thing is put into fluid bed, inlet temperature is 45 ℃, and 35 ℃ of leaving air temps spray into the coating solution that modulates with methylcellulose and carry out Cotton seeds, continued dry 25 minutes coated back, namely gets the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid.The solid content of coating solution is 10%.
Embodiment 3:
The safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid, comprise coating and the medicine carrying ball heart, the described medicine carrying ball heart is that size is not more than 30 purpose micropartical, and wherein medicine carrying ball pericardium contains the component of following percetage by weight: safe ten thousand rhzomorphs 10% of tartaric acid, sulfadimidine 10%, lactose 10%; Maize cob meal 15%, starch 31%, microcrystalline Cellulose 20%, granulation binders 4%.
Wherein, described granulation binders is the mixture of polyethylene pyrrolidone and Polyethylene Glycol.Described coat weight is 3% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid, and wherein coating material is hydroxypropyl emthylcellulose.
The preparation method of the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid comprises following concrete steps:
1) by following each component of following percentage by weight difference weighing: the mixed type granulation binders 4% of safe ten thousand rhzomorphs 10% of tartaric acid, sulfadimidine 10%, lactose 10%, maize cob meal 15%, starch 31%, microcrystalline Cellulose 20%, polyethylene pyrrolidone and Polyethylene Glycol.With safe ten thousand rhzomorphs of tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose mix homogeneously;
2) add in the granulation binders for preparing in the step 1) gained mixture and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, dry back screening 30-50 purpose screening thing;
4) step 3) gained screening thing is put into fluid bed, inlet temperature is 55 ℃, and 30 ℃ of leaving air temps spray into the coating solution that modulates with sodium carboxymethyl cellulose and carry out Cotton seeds, continued dry 20 minutes coated back, namely gets the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid.The solid content of coating solution is 10%.
Embodiment 4:
The safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid, comprise coating and the medicine carrying ball heart, the described medicine carrying ball heart is that size is not more than 30 purpose micropartical, wherein medicine carrying ball pericardium contains the component of following percetage by weight: safe ten thousand rhzomorphs 20% of tartaric acid, sulfadimidine 20%, lactose 5%, maize cob meal 10%, starch 7%, microcrystalline Cellulose 30%, granulation binders 8%.
Wherein, described granulation binders is the sodium carboxymethyl cellulose binding agent.Described coat weight is 5% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid, and wherein coating material is hydroxypropyl emthylcellulose.
The preparation method of the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid comprises following concrete steps:
1) by following each component of following percentage by weight difference weighing: safe ten thousand rhzomorphs 20% of tartaric acid, sulfadimidine 20%, lactose 5%, maize cob meal 10%, starch 7%, microcrystalline Cellulose 30%, sodium carboxymethyl cellulose granulation binders 8%.With safe ten thousand rhzomorphs of tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose mix homogeneously;
2) add in the granulation binders for preparing in the step 1) gained mixture and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, dry back screening 30-50 purpose screening thing;
4) step 3) gained screening thing is put into fluid bed, inlet temperature is 55 ℃, and 35 ℃ of leaving air temps spray into the coating solution that modulates with hydroxyethyl-cellulose and sodium carboxymethyl cellulose and carry out Cotton seeds, continued dry 25 minutes coated back, namely gets the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid.The solid content of coating solution is 10%.
Embodiment 5:
The safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid, comprise coating and the medicine carrying ball heart, the described medicine carrying ball heart is that size is not more than 30 purpose micropartical, wherein medicine carrying ball pericardium contains the component of following percetage by weight: safe ten thousand rhzomorphs 25% of tartaric acid, sulfadimidine 25%, lactose 5%, maize cob meal 5%, starch 5%, microcrystalline Cellulose 30%, granulation binders 5%.
Wherein, described granulation binders is the mixed type binding agent of hydroxypropyl emthylcellulose and methylcellulose.Described coat weight is 6% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid, and wherein coating material is hydroxypropyl emthylcellulose.
The preparation method of the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid comprises following concrete steps:
1) by following each component of following percentage by weight difference weighing: the mixed type granulation binders 5% of safe ten thousand rhzomorphs 25% of tartaric acid, sulfadimidine 25%, lactose 5%, maize cob meal 5%, starch 5%, microcrystalline Cellulose 30%, hydroxypropyl emthylcellulose and methylcellulose.With safe ten thousand rhzomorphs of tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose mix homogeneously;
2) add in the granulation binders for preparing in the step 1) gained mixture and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, dry back screening 30-50 purpose screening thing;
4) step 3) gained screening thing is put into fluid bed, inlet temperature is 55 ℃, and 35 ℃ of leaving air temps spray into the coating solution that modulates with hydroxypropyl emthylcellulose and ethyl vitamin and carry out Cotton seeds, continued dry 30 minutes coated back, namely gets the safe ten thousand rhzomorph micropills of described compound recipe tartaric acid.The solid content of coating solution is 10%.
Below clinical efficacy by the safe ten thousand rhzomorph micropills of zoopery explanation compound recipe tartaric acid of the present invention.
Choose 80 of the growing and fattening pigs that one large-scale pig farm, Guangdong is basic identical from numerous autotrophy, feeding and management condition, the birth age in days is close, be diagnosed as respiratory tract disease, be divided into 2 groups at random, be i.e. experimental group, matched group, 40 every group.Experimental group gives to use by the safe ten thousand rhzomorph micropill 25g/ ton feed mixings of the compound recipe tartaric acid of embodiment 3 preparations, matched group gives to prepare voluntarily with the safe ten thousand rhzomorph micropills of the tartaric acid of embodiment 3 preparations and uses with safe ten thousand rhzomorph pre-mixing agents (carrier is starch) the 40g/ ton feed mixing of the common tartaric acid of content, and two groups of feedings and managements are identical.
Curative effect judge to be cured: the symptom complete obiteration after 2～3 times of offer medicine, and the cough complete obiteration, appetite, the normal person of body temperature are healing.Effectively: offer medicine after 4～5 times, spirit, appetite take a turn for the better, sx, and cough obviously alleviates to effectively.Inefficiency: after death or the medication 6～7 times, symptom does not alleviate or continues and worsens to invalid, calculates in every group accordingly and fails to respond to any medical treatment in the medication.
Experimental result: show through clinical observation on the therapeutic effect statistics: the cure rate of experimental group is 87.5% (35/40), effective percentage is 92.5%(37/40), inefficiency 7.5% (3/40), matched group be respectively 70%(28/40), 80%(32/40), 20%(8/40).
Experiment conclusion: the effective percentage of experimental group is higher by 12.5% than matched group, difference is (p＜0.01) extremely significantly, this shows that the safe ten thousand rhzomorph micropills of compound recipe tartaric acid of the present invention embodying than the better clinical effectiveness of common pre-mixing agent aspect the treatment porcine respiratory disease and having reduced the use amount of safe ten thousand rhzomorphs of tartaric acid, have saved production cost.
For a person skilled in the art, can make other various corresponding changes and distortion according to technical scheme described above and design, and these all changes and distortion should belong within the protection domain of claim of the present invention all.
Claims (7)
1. the safe ten thousand rhzomorph micropills of compound recipe tartaric acid is characterized in that, are made by the coating material parcel medicine carrying ball heart;
1) described medicine carrying ball pericardium is drawn together following components in weight percentage content: the safe ten thousand rhzomorph 1-30% of tartaric acid, sulfadimidine 1-30%, lactose 5-20%, maize cob meal 5-25%, starch 10-60%, microcrystalline Cellulose 15-35%, granulation binders 0.5-12%;
2) described coating material weight is no more than 8% of the safe ten thousand rhzomorph micropill gross weights of described compound recipe tartaric acid; Coating material is selected from one or more in hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, sodium carboxymethyl cellulose, methylethylcellulose, Polyethylene Glycol, the polyvinylpyrrolidone.
2. safe ten thousand rhzomorph micropills of compound recipe tartaric acid according to claim 1, it is characterized in that: described medicine carrying ball pericardium is drawn together following components in weight percentage content: the safe ten thousand rhzomorph 5-20% of tartaric acid; Sulfadimidine 5-20%; Lactose 10-15%; Maize cob meal 10-20%; Starch 20-50%; Microcrystalline Cellulose 15-30%; Granulation binders 1-8%.
3. safe ten thousand rhzomorph micropills of compound recipe tartaric acid according to claim 1 and 2, it is characterized in that: the described medicine carrying ball heart is that size is not more than 30 purpose micropartical.
4. safe ten thousand rhzomorph micropills of compound recipe tartaric acid according to claim 1 and 2 is characterized in that: described granulation binders is selected from one or more the compositions in gelatin, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, methylcellulose, ethyl cellulose or the starch slurry.
5. the preparation method of the safe ten thousand rhzomorph micropills of a kind of compound recipe tartaric acid according to claim 1 and 2 is characterized in that carrying out according to the following steps:
1) by one or more the compositions in prescription weighing gelatin, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, methylcellulose, ethyl cellulose or the starch, as granulation binders;
2) by safe ten thousand rhzomorphs of prescription weighing tartaric acid, sulfadimidine, lactose, maize cob meal, starch, microcrystalline Cellulose and mix homogeneously, add step 1) gained granulation binders again and make soft material, via extrude, ball blast makes the medicine carrying ball heart;
3) with step 2) the gained medicine carrying ball heart carries out drying, sieves out 30-50 purpose screening thing after the drying;
4) the one or more combination thing in hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, sodium carboxymethyl cellulose, methylethylcellulose, Polyethylene Glycol, the polyvinylpyrrolidone being prepared in advance solid content is 10% coating solution, then step 3) gained screening thing is sprayed into and carry out Cotton seeds in the coating solution, coated back is continued dry, namely gets the safe ten thousand rhzomorph micropills of described tartaric acid.
6. the preparation method of the safe ten thousand rhzomorph micropills of compound recipe tartaric acid according to claim 5 is characterized in that: in step 3), the described medicine carrying ball heart is put into fluid bed carry out drying.
7. the preparation method of the safe ten thousand rhzomorph micropills of compound recipe tartaric acid according to claim 5, it is characterized in that: in step 4), the screening thing that screening is good is put into fluid bed, and inlet temperature is 40-60 ℃, spray into the coating solution Cotton seeds, dry 15-30 minute of the follow-up afterflowization of coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310187035.6A CN103271931B (en) | 2013-05-20 | 2013-05-20 | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310187035.6A CN103271931B (en) | 2013-05-20 | 2013-05-20 | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103271931A true CN103271931A (en) | 2013-09-04 |
| CN103271931B CN103271931B (en) | 2015-04-22 |
Family
ID=49054175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310187035.6A Expired - Fee Related CN103271931B (en) | 2013-05-20 | 2013-05-20 | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103271931B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107281158A (en) * | 2016-04-12 | 2017-10-24 | 王玉万 | Capsule core material and its micro-capsule containing tylosin are prepared with tylosin anti-stripping agent |
| CN107496436A (en) * | 2017-10-19 | 2017-12-22 | 洛阳瑞华动物保健品有限公司 | A kind of Tylosin Tartrate sulfadimidine sustained release pellet and preparation method thereof |
| CN107753436A (en) * | 2017-10-31 | 2018-03-06 | 成都乾坤动物药业股份有限公司 | A kind of new safe ten thousand rhzomorphs pre-mixing agent and its preparation technology and application |
| CN108261410A (en) * | 2016-12-30 | 2018-07-10 | 武汉回盛生物科技股份有限公司 | A kind of safe ten thousand rhzomorphs inclusion enteric coated preparations of tartaric acid and preparation method |
| CN114028338A (en) * | 2021-12-28 | 2022-02-11 | 江西英特科胜动保科技有限公司 | Preparation method and application of water-soluble tylosin tartrate premix |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450065A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Powder for treating livestock and poultry mycoplasma infection |
| CN102274178A (en) * | 2011-08-25 | 2011-12-14 | 西北农林科技大学 | Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof |
| CN102526054A (en) * | 2012-02-23 | 2012-07-04 | 广东大华农动物保健品股份有限公司 | Compound enrofloxacin pellets and preparation method thereof |
-
2013
- 2013-05-20 CN CN201310187035.6A patent/CN103271931B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450065A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Powder for treating livestock and poultry mycoplasma infection |
| CN102274178A (en) * | 2011-08-25 | 2011-12-14 | 西北农林科技大学 | Acetyl-isovaleryl tylosin nanoemulsion medicine and preparation method thereof |
| CN102526054A (en) * | 2012-02-23 | 2012-07-04 | 广东大华农动物保健品股份有限公司 | Compound enrofloxacin pellets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 赵林: "挤出滚圆法制备微丸辅料用的研究进展", 《中国兽药杂志》, vol. 46, no. 11, 31 December 2012 (2012-12-31), pages 58 - 61 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107281158A (en) * | 2016-04-12 | 2017-10-24 | 王玉万 | Capsule core material and its micro-capsule containing tylosin are prepared with tylosin anti-stripping agent |
| CN108261410A (en) * | 2016-12-30 | 2018-07-10 | 武汉回盛生物科技股份有限公司 | A kind of safe ten thousand rhzomorphs inclusion enteric coated preparations of tartaric acid and preparation method |
| CN108261410B (en) * | 2016-12-30 | 2020-10-27 | 武汉回盛生物科技股份有限公司 | Tylosin tartrate inclusion enteric-coated preparation and preparation method thereof |
| CN107496436A (en) * | 2017-10-19 | 2017-12-22 | 洛阳瑞华动物保健品有限公司 | A kind of Tylosin Tartrate sulfadimidine sustained release pellet and preparation method thereof |
| CN107753436A (en) * | 2017-10-31 | 2018-03-06 | 成都乾坤动物药业股份有限公司 | A kind of new safe ten thousand rhzomorphs pre-mixing agent and its preparation technology and application |
| CN107753436B (en) * | 2017-10-31 | 2019-10-22 | 成都乾坤动物药业股份有限公司 | A kind of safe ten thousand rhzomorphs pre-mixing agent and the preparation method and application thereof |
| CN114028338A (en) * | 2021-12-28 | 2022-02-11 | 江西英特科胜动保科技有限公司 | Preparation method and application of water-soluble tylosin tartrate premix |
| CN114028338B (en) * | 2021-12-28 | 2023-11-03 | 江西英特科胜动保科技有限公司 | Preparation method and application of water-soluble telavancin tartrate premix |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103271931B (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103271931B (en) | Compound acetylisovalery tylosin tartrate pellet and preparation method thereof | |
| CN101690717B (en) | Valnemulin for livestock and saline premix and preparation method thereof | |
| CN102526054B (en) | Compound enrofloxacin pellets and preparation method thereof | |
| CN104397349A (en) | Feeding intestinal tract sustained-release type compound acidifier and preparation method thereof | |
| CN108261410B (en) | Tylosin tartrate inclusion enteric-coated preparation and preparation method thereof | |
| CN106176680A (en) | A kind of enteric tilmicosin slow-releasing microcapsule and preparation method thereof | |
| CN107737106A (en) | Safe ten thousand rhzomorph sol particles of a kind of tartaric acid and preparation method thereof | |
| CN105125524A (en) | Tilmicosin enteric-coated pellets and preparation method thereof | |
| CN102885201B (en) | Compound Chinese herbal medicine feed additive | |
| CN103285374A (en) | Amoxicillin colistin sulphate granule and preparation method thereof | |
| CN101543601B (en) | Compound pharmaceutical composition for preventing and curing respiratory diseases in animals and preparation method thereof | |
| CN110075082B (en) | Enrofloxacin quick-release pellet and preparation method thereof | |
| CN101496811A (en) | Soluble and stable tilmicosin composition | |
| CN101011408A (en) | Animal-used compound preparation for treating parasitic disease in or out of livestock and fowl body and preparation method thereof | |
| CN107375247B (en) | Tilmicosin film-controlled enteric sustained-release preparation and preparation method thereof | |
| CN103652366A (en) | Stable mercaptamine enveloped by microcapsules and preparation method thereof | |
| CN103239422A (en) | Preparation method of smellless coated enrofloxacin preparation | |
| CN108324700A (en) | A kind of enteric slow release oxytetracycline calcium pre-mixing agent and preparation method thereof | |
| CN108991246A (en) | A kind of functional form additive for farm animal feed and the preparation method and application thereof | |
| CN104127389A (en) | Praziquantel chewing tablet for pets and preparation method thereof | |
| CN102835567A (en) | Traditional Chinese medicine-containing feed premix for preventing respiratory disease | |
| CN103251552B (en) | Enrofloxacin cataplasm and preparation method thereof | |
| CN106362159A (en) | Molecular skeleton type tilmicosin sustained release preparation and preparation method thereof | |
| CN102302454A (en) | Animal intestinal slow-releasing parasiticide and preparation method | |
| CN102172358B (en) | Timicosin compound preparation and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Xiaoyan Inventor after: Fang Binghu Inventor after: Chen Ruiai Inventor after: Yuan Zhaohong Inventor after: Zhan Suizhang Inventor before: Liu Xiaoyan Inventor before: Fang Fanhu Inventor before: Chen Ruiai Inventor before: Yuan Zhaohong Inventor before: Zhan Suizhang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XIAOYAN FANG FANHU CHEN RUIAI YUAN ZHAOHONG ZHAN HUIZHANG TO: LIU XIAOYAN FANG BINGHU CHEN RUIAI YUAN ZHAOHONG ZHAN HUIZHANG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160617 Address after: 527400 Yunfu City, Xinxing County Province, the new town of North East embankment road, No. 6 Patentee after: GUANGDONG WENS DAHUANONG BIOTECHNOLOGY CO., LTD. Address before: 527400, No. 2, Wen Science Park, east north embankment road, Xinxing County new town, Guangdong, Yunfu, three Patentee before: Guangdong Dahuanong Animal Health Products Co., Ltd. Patentee before: Zhaoqing Dahuanong Biological Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150422 Termination date: 20190520 |